Dr Prem'S Molecules Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 21 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 19.22%
- Profit Growth 177.19%
- Ebitda 496.98%
- Net Worth 38.17%
- Total Assets -40.45%
About Dr Prem'S Molecules
Dr Prem's Molecules Private Limited (DPMPL) is a Private Limited Indian Non-Government Company incorporated in India on 01 September 2003 and has a history of 21 years and five months. Its registered office is in Vadodara, Gujarat, India.
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Jyothi Vuppalapaty and Premsagar Vuppalapaty serve as directors at the Company.
Company Details
-
Location
Vadodara, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24231GJ2003PTC042839
-
Company No.
042839
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
01 Sep 2003
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Dr Prem'S Molecules?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Premsagar Vuppalapaty
|
Managing Director | 01-Sep-2003 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Jyothi Vuppalapaty
|
Director | 01-Sep-2003 | Current |
Financial Performance of Dr Prem'S Molecules.
Dr Prem'S Molecules Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 19.22% increase. The company also saw a substantial improvement in profitability, with a 177.19% increase in profit. The company's net worth Soared by an impressive increase of 38.17%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dr Prem'S Molecules?
In 2018, Dr Prem'S Molecules had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Dr Prem'S Molecules?
Unlock and access historical data on people associated with Dr Prem'S Molecules, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dr Prem'S Molecules, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dr Prem'S Molecules's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
